GLP-1 Medications and Atrial Fibrillation: What the Research Shows

Atrial fibrillation is the most common serious heart rhythm disorder in the United States, affecting an estimated 3.5 to 6 million adults. It causes the upper chambers of the heart to beat irregularly, raising the risk of stroke by up to fivefold. And obesity, one of the primary conditions that GLP-1 medications address, is among the strongest modifiable risk factors for developing it.

That intersection has drawn real scientific attention over the past several years. Multiple systematic reviews and meta-analyses, published between 2024 and 2026, have now examined whether GLP-1 receptor agonists reduce atrial fibrillation risk in people with overweight or obesity. The findings are cautiously promising.

This article explains what that research shows, why it matters, and what it means for people considering medically supervised weight management.

*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. The studies described in this article were conducted primarily using FDA-approved branded versions of these drugs. Results may not apply to compounded formulations. This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting or changing any medication, especially if you have a history of heart rhythm problems.*

---

What Is Atrial Fibrillation?

Atrial fibrillation, or AF, happens when the electrical signals that coordinate heartbeat become chaotic in the upper chambers of the heart (the atria). Instead of a steady, organized squeeze, the atria quiver rapidly. The lower chambers still pump blood, but the timing is irregular, and blood can pool and form clots in the atria. Those clots can travel to the brain and cause a stroke.

Common symptoms include palpitations, a racing or fluttery heartbeat, fatigue, shortness of breath, and lightheadedness. Some people have no symptoms at all, which is part of what makes AF easy to miss.

Treatment depends on severity and individual health factors. Options include rate control medications, rhythm control medications, blood thinners, and procedures like cardioversion or catheter ablation. Weight management has long been recognized as a meaningful part of AF care, because obesity contributes to AF through several direct physiological pathways.

---

How Obesity Contributes to Atrial Fibrillation

The link between obesity and AF is well established. Excess body weight promotes AF through at least three mechanisms.

Structural changes in the heart. Obesity causes the atria to stretch and enlarge over time. Stretched cardiac tissue conducts electrical signals more erratically, creating conditions where AF is more likely to start and persist. Fat deposits around the heart, particularly near the atria, add to this structural disruption.

Chronic inflammation. Adipose tissue, especially visceral fat, releases inflammatory proteins called cytokines. Sustained low-grade inflammation damages the delicate electrical system in the heart and contributes to tissue scarring, both of which increase AF risk.

Metabolic factors. High blood pressure, insulin resistance, and obstructive sleep apnea all commonly accompany obesity and independently raise AF risk. These conditions together compound the effect on heart rhythm.

Weight loss addresses all three. Research has shown that intentional weight reduction reduces atrial size, lowers inflammatory markers, and improves blood pressure and metabolic function. The key question for the GLP-1 research is whether the drugs add benefit beyond weight loss alone, or whether the benefit tracks with how much weight is lost.

---

What Clinical Research Shows

Several independent research teams have now analyzed the relationship between GLP-1 medications and atrial fibrillation. Here is what the main studies found.

A 2024 Meta-Analysis on Semaglutide and AF Prevention

A systematic review and meta-analysis published in *Diabetes, Metabolism and Syndrome* in June 2024 specifically examined semaglutide's potential role in preventing atrial fibrillation (PMID 38955095, Zhang HD). The researchers pooled data from multiple randomized controlled trials and observational studies. Their analysis found that semaglutide use was associated with a meaningful reduction in AF incidence. The authors concluded that the cardioprotective effects likely involve both the weight loss produced by the drug and direct anti-inflammatory effects on cardiac tissue.

This was one of the first papers to treat AF as a primary endpoint rather than a secondary finding within a broader cardiovascular outcome trial.

A 2025 Systematic Review on Semaglutide and Arrhythmia

A broader systematic review and meta-analysis published in the *European Journal of Medical Research* in September 2025 examined semaglutide's effects on arrhythmic events, major cardiovascular outcomes, and renal outcomes in people with overweight or obesity (PMID 40890879, Wu R). The analysis confirmed that semaglutide was associated with reduced arrhythmic events, with effects spanning AF and other rhythm-related endpoints. The authors noted that the findings were consistent across subgroups and were not explained solely by blood pressure reduction.

This is significant because it suggests the rhythm effect may be partly independent of changes in traditional cardiovascular risk factors.

A 2026 Meta-Analysis Covering GLP-1 Receptor Agonists Broadly

A meta-analysis published in *Metabolism* in February 2026 examined the full class of GLP-1 receptor agonists, including both GLP-1 single agonists (like semaglutide) and dual GIP/GLP-1 agonists (like tirzepatide), specifically for their effects on atrial fibrillation risk in people with overweight or obesity (PMID 41349790, Karakasis P). The analysis pooled data from randomized controlled trials and found that GLP-1 class treatment was associated with a statistically significant reduction in AF risk. The authors called for further dedicated trials to confirm the mechanism.

<img src="/images/articles/glp1-medications-heart-failure-hfpef-hero.jpeg" alt="Close-up of a cardiac monitoring device with healthcare provider in background, representing cardiac research on GLP-1 medications and heart rhythm" style={{ borderRadius: '12px', margin: '2rem 0' }} />

Tirzepatide and Cardiac Rhythm Surveillance

A 2026 pharmacovigilance analysis published in *Frontiers in Pharmacology* examined real-world adverse event reports for tirzepatide, including arrhythmias and other cardiovascular signals (PMID 41948731, Chen D). The analysis found no elevated arrhythmia signal attributable to tirzepatide itself. In fact, the data were consistent with the broader pattern seen in the GLP-1 class: heart failure and arrhythmic events were not elevated, and several cardiovascular signals trended favorably compared to background rates.

This kind of pharmacovigilance data complements clinical trial findings, as it captures patterns in a much broader and more diverse real-world population.

---

Why This Research Matters (and What It Does Not Prove)

The body of evidence reviewed above consistently points in the same direction: GLP-1 receptor agonists, as a class, appear to reduce atrial fibrillation risk in people with overweight or obesity. The reduction shows up across study types, across individual drugs in the class, and across diverse patient populations.

But several important caveats apply.

Most studies were not designed specifically to measure AF. AF often appears as a secondary or exploratory endpoint in large cardiovascular trials. Dedicated AF outcome trials for GLP-1 medications are still limited, though this is changing.

Weight loss alone may explain much of the benefit. It is difficult to separate the direct cardiac effects of GLP-1 medications from the indirect effects of the weight loss they produce. Studies that attempt to control for weight change generally still find some benefit, suggesting there may be a weight-independent effect, but this is not conclusively established.

These medications are not a treatment for atrial fibrillation. GLP-1 medications are prescribed for weight management and blood sugar control. If you have atrial fibrillation, your cardiologist's treatment plan remains the appropriate standard of care. The research described here is about risk reduction, not rhythm management.

Compounded medications were not used in these studies. The trials that generated this evidence used FDA-approved branded drugs. Compounded semaglutide and tirzepatide are prepared by 503A compounding pharmacies based on individual patient prescriptions. They are not FDA-approved and have not been studied in cardiovascular outcome trials.

---

Who Might Benefit Most

The research suggests the strongest potential signal in people who are overweight or obese and who already have cardiovascular risk factors. That overlaps considerably with the population for whom GLP-1 medications are typically prescribed.

People with obesity who also have hypertension, type 2 diabetes, metabolic syndrome, or sleep apnea already carry elevated AF risk. If GLP-1 medications reduce that risk through weight loss, inflammation reduction, and improved metabolic function, the benefit compounds. That said, no set of findings from population-level trials guarantees any individual outcome.

---

What to Discuss With Your Provider

If you are considering GLP-1 medications and have a history of atrial fibrillation or concerns about your heart rhythm, this is worth discussing with both your primary care provider and, if relevant, your cardiologist.

A few questions worth raising:

• Does the potential cardiovascular benefit of GLP-1 treatment apply to my situation, given my specific AF history and risk factors?
• How does weight management fit into my overall AF management plan?
• Are there any contraindications or drug interactions between GLP-1 medications and my current AF medications?

Prescriva's program includes a thorough medical evaluation with a licensed provider before any treatment begins. That evaluation is the appropriate place to review your cardiovascular history and determine whether a medically supervised weight management program is appropriate for you.

---

Summary

Atrial fibrillation and obesity are closely linked through shared mechanisms: atrial enlargement, chronic inflammation, metabolic dysfunction, and high blood pressure. GLP-1 receptor agonists address several of these pathways simultaneously. A growing body of evidence from 2024 to 2026 suggests that GLP-1 medications reduce AF risk in people with overweight or obesity. Multiple meta-analyses and systematic reviews point in the same direction.

This does not make GLP-1 medications a treatment for atrial fibrillation. But for people who qualify for medically supervised weight management, the cardiovascular data add meaningful context to an already compelling case for addressing excess weight.

As with all research in this area, the evidence continues to evolve. Dedicated trials focused specifically on GLP-1 medications and heart rhythm are expected to provide clearer answers in the coming years.

---

References

1. Zhang HD, et al. Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis. *Diabetes Metab Syndr.* 2024 Jun. PMID: 38955095.

1. Wu R, et al. Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis. *Eur J Med Res.* 2025 Sep 2. PMID: 40890879.

1. Karakasis P, et al. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials. *Metabolism.* 2026 Feb. PMID: 41349790.

1. Chen D, et al. Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events. *Front Pharmacol.* 2026. PMID: 41948731.

---

*This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. Results described in clinical studies were conducted using FDA-approved branded formulations. Individual results vary. Consult a licensed healthcare provider before starting any new medication. Prescriva connects you with independently licensed healthcare providers who make all clinical decisions.*